GlassScriptPhysician profile
Melissa Joseph
NPI 1366814931
$82,272.18
in general payments reported to CMS, 2019-2025
23 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,292 · 2022: $2,885 · 2023: $13K · 2024: $21K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $12K · Food and Beverage: $12K · Travel and Lodging: $4,912 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,187.50 |
| Consulting Fee | $11,897.50 |
| Food and Beverage | $11,788.84 |
| Travel and Lodging | $4,911.98 |
| Education | $309.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,610.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26,027.64 | 2021-2025 | Caplyta |
| Alkermes, INC. | $10,184.99 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $6,686.57 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $2,399.81 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,861.52 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,711.87 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Indivior INC. | $701.02 | 2021-2025 | Sublocade, Perseris |
| Lundbeck LLC | $490.38 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $342.51 | 2022-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $292.80 | 2021-2023 | Trintellix |
| Braeburn INC. | $208.54 | 2023-2025 | Brixadi |
| Uswm, LLC | $143.12 | 2023-2024 | Lucemyra, Zimhi |
| Orexo US, INC. | $119.16 | 2022-2025 | Zubsolv |
| Sage Therapeutics, LLC | $112.79 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $94.10 | 2023 | Invega Sustenna, Invega Trinza |
| Inspire Medical Systems, INC. | $92.40 | 2025 | Inspire |
| Eisai INC. | $81.60 | 2021 | |
| Collegium Pharmaceutical, INC. | $41.05 | 2024-2025 | Xtampza, Jornay Pm |
| Owp Pharmaceuticals, INC. | $22.85 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.55 | 2021 | |
| Pear Therapeutics (US), INC. | $15.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.10 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.